Open the mobile version, with barcode scanning
Class II Ongoing

Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), packaged in a) 90-count bottles (NDC 16729-456-15), and b) 1000-count bottles (NDC 16729-456-17), Rx Only, Manufactured for: Accord Healthcare, I…

Why: Subpotent Drug

Company
ACCORD HEALTHCARE, INC.
Raleigh, NC, United States
Reported
Sep 2, 2026
Recall started
Aug 6, 2026
Where sold
Nationwide within the United States
Amount
N/A
Full product description
Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), packaged in a) 90-count bottles (NDC 16729-456-15), and b) 1000-count bottles (NDC 16729-456-17), Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India.
Lots / codes affected
a) Lot #: D2402642, Exp. Date 11/30/2026 b) Lot #: D2401832, Exp. Date 08/31/2026; D2402525, D2402527, D2402526, D2402644, D2402643, Exp. Date 11/30/2026.

Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.